Write your message
Volume 5, Issue 1 (Winter 2020)                   J Obstet Gynecol Cancer Res 2020, 5(1): 2-2 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Arab M. Fertility Preservation and Important Tips of Cancer in Adolescent and Young Adult (AYA). J Obstet Gynecol Cancer Res. 2020; 5 (1) :2-2
URL: http://jogcr.com/article-1-235-en.html
Abstract:   (85 Views)
Cancer in adolescent and young adults (AYA) includes people who are diagnosed with cancer at the age of 15–39. One of the main concerns and consequences of AYA cancer treatment in both sexes is infertility. Premature ovarian failure (POF) is common in multimodal chemotherapy regimens. There is a significant difference in the sensitivity of the ovary to drugs.
 
In conclusion, in young cancer women, oophoropexy, infertility counseling, and embryo or oocyte cryopreservation should be considered. Medroxyprogesterone, oral contraceptive pill (OCP), or gonadotropin-releasing hormone (GnRH) should be prescribed in the risk of menorrhagia.
     
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2019/10/12 | Accepted: 2020/06/16 | Published: 2020/01/10

References
1. Chan JL, Letourneau J, Salem W, et al. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. J Cancer Surviv 2017 Feb 1;11(1):58-63. [DOI:10.1007/s11764-016-0563-2] [PMID] [PMCID]
2. Bleyer A, O'Leary M, Barr R, Ries L. Cancer Epidemiology in older Adolescents and Young Adults 15 to 29 Years of age, including SEER incidence and survival: 1975-2000. National cancer institute, NIH pub. No. 06-5767 2006.
3. Bleyer A, Budd T, Montello M. Adolescents and Young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006 Oct 1;107(S7):1645-55. [DOI:10.1002/cncr.22102] [PMID]
4. Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol 2010 Nov 10;28(32):4800-9. [DOI:10.1200/JCO.2009.22.2802] [PMID]
5. Kondryn HJ, Edmondson CL, Hill J, Eden TO. Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol 2011 Jan 1;12(1):100-8. [DOI:10.1016/S1470-2045(10)70069-3]
6. Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS, Ginsberg JP, Kenney LB, Levine JM, Robison LL, Shnorhavorian M. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016 May 1;17(5):567-76. [DOI:10.1016/S1470-2045(16)00086-3]
7. Metzger ML, Meacham LR, Patterson B, Casillas JS, Constine LS, Hijiya N, Kenney LB, Leonard M, Lockart BA, Likes W, Green DM. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013 Mar 20;31(9):1239-47. [DOI:10.1200/JCO.2012.43.5511] [PMID] [PMCID]
8. Haukvik UKH, Dieset I, Bjoro T, et al. Treatment- related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol. 2006 Sep 1;17(9):1428-33.. [DOI:10.1093/annonc/mdl149] [PMID]
9. Bramswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol 2015 Jun 1;16(6):667-75. [DOI:10.1016/S1470-2045(15)70140-3]
10. De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van't Veer MB, Aleman BM, van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood, J Am Soc Hematol. 2008 Jan 1;111(1):101-8. [DOI:10.1182/blood-2007-05-090225] [PMID]
11. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL, Sklar CA. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metabol. 2006 May 1;91(5):1723-8. [DOI:10.1210/jc.2006-0020] [PMID]
12. Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncol. 2015 Nov;20(11):1283. [DOI:10.1634/theoncologist.2015-0223] [PMID] [PMCID]
13. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014 Jun 1;40(5):675-83. [DOI:10.1016/j.ctrv.2013.12.001] [PMID]
14. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011 Jun 10;29(17):2334-41. [DOI:10.1200/JCO.2010.32.5704] [PMID]
15. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New Eng J Med. 2015 Mar 5;372(10):923-32. [DOI:10.1056/NEJMoa1413204] [PMID] [PMCID]
16. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J clin oncol 1996;14:1718-1729. [DOI:10.1200/JCO.1996.14.5.1718] [PMID]
17. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Ocnol 2013;31:2500-2510. [DOI:10.1200/JCO.2013.49.2678] [PMID] [PMCID]
18. Waimey KE, Duncan FE, Su HL, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 oncofertilty consortium conference. J Adolesc young adult oncol 2013;2:25-30. [DOI:10.1089/jayao.2012.0035] [PMID] [PMCID]
19. Terenziani M, Piva L, Meazz C, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil steril 2009;91:935 e 915-936. [DOI:10.1016/j.fertnstert.2008.09.029] [PMID]
20. Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J clin oncol 2015;33:2424-2429. [DOI:10.1200/JCO.2014.59.3723] [PMID] [PMCID]
21. Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo- banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum reprod 2010;25:2239-2246. [DOI:10.1093/humrep/deq146] [PMID]
22. Rienzi L, Romano S, Albricci L, et al. Embryo development of fresh 'Versus' vitrified metaphase ii oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum reprod 2010;25:66-73. [DOI:10.1093/humrep/dep346] [PMID] [PMCID]
23. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk andwhat can be offered? Lancet Oncol 2005;6:209-218. [DOI:10.1016/S1470-2045(05)70092-9]
24. Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the childhood cancer survivor study cohort. Lancet Oncol 2013;14:873-881. [DOI:10.1016/S1470-2045(13)70251-1]
25. Mature oocyte cryopreservation: a guidline. Fertility and sterility 2013;--:37-43 [DOI:10.1016/j.fertnstert.2012.09.028] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.